Top-News
Biotechnologie USA

Akero News

Aktie
WKN:  A2PLNP ISIN:  US00973Y1082 US-Symbol:  AKRO
21,98 €
+2,195 €
+11,09%
28.06.24
Handeln Depot/Watchlist
Aktienanzahl *
55,60 Mio.
Marktkapitalisierung *
1,10 Mrd. €
Streubesitz
-14,19%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.10.2023

Akero News

25.06.24 - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ak
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ak PR Newswire
25.06.24 - PR Newswire
AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
24.06.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO PR Newswire
22.06.24 - PR Newswire
AKRO Investors Have the Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have the Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
21.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
19.06.24 - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics PR Newswire
18.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
18.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
17.06.24 - PR Newswire
Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, LLP
Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, ...
15.06.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO PR Newswire
14.06.24 - PR Newswire
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit ...
13.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
13.06.24 - PR Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics PR Newswire
13.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
07.06.24 - PR Newswire
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF ...
07.06.24 - PR Newswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
07.06.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO PR Newswire
06.06.24 - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics PR Newswire
05.06.24 - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO PR ...
05.06.24 - PR Newswire
IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm PR Newswire

Newssuche

Videos

newspaper
03.07.24
Technical Trading: Bund Future Long Chance
Bund Future Long Typ: Turbo Open End WKN: VM3CG4 Hebel: 7,32 Laufzeit: OpenEnd Einstieg: Market ... Mehr »